tradingkey.logo

Labcorp Holdings Inc

LH

261.500USD

+1.420+0.55%
收盘 08/01, 16:00美东报价延迟15分钟
21.68B总市值
29.66市盈率 TTM

Labcorp Holdings Inc

261.500

+1.420+0.55%
关于 Labcorp Holdings Inc 公司
Labcorp Holdings Inc. 提供全面的实验室服务,帮助医生、医院、制药公司、研究人员和患者做出清晰而自信的决定。该公司通过其无与伦比的诊断和药物开发能力提供见解并加速改善健康和改善生活。该公司通过两个部门运营:诊断实验室 (Dx) 和生物制药实验室服务 (BLS)。诊断实验室部门包括常规测试和专业/深奥测试。Dx 通过患者服务中心、分支机构、快速反应实验室、初级实验室和专业实验室网络运营。生物制药实验室服务部门包括早期开发研究实验室和中央实验室服务。该公司专注于四个主要专业测试领域,例如肿瘤学、女性健康、自身免疫性疾病和神经病学。
公司简介
公司代码LH
公司名称Labcorp Holdings Inc
上市日期Apr 24, 1991
成立日期2024
CEOMr. Adam H. Schechter
员工数量70000
证券类型Ordinary Share
年结日Apr 24
公司地址358 S Main St
城市BURLINGTON
上市交易所NYSE Consolidated
国家United States of America
邮编27215
电话13362291127
网址https://www.labcorp.com/
公司代码LH
上市日期Apr 24, 1991
成立日期2024
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Adam H. Schechter
Mr. Adam H. Schechter
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
98.96K
-5.81%
Dr. Brian J. Caveney, M.D., J.D.
Dr. Brian J. Caveney, M.D., J.D.
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
30.07K
-6.24%
Mr. Lance V. Berberian
Mr. Lance V. Berberian
Executive Vice President - Special Advisor, Strategy
Executive Vice President - Special Advisor, Strategy
22.53K
+9.59%
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Independent Director
Independent Director
12.89K
--
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Lead Independent Director
Lead Independent Director
12.84K
--
Ms. Richelle P. Parham
Ms. Richelle P. Parham
Independent Director
Independent Director
9.48K
--
Ms. Amy B. Summy
Ms. Amy B. Summy
Executive Vice President, Chief Marketing Officer
Executive Vice President, Chief Marketing Officer
5.30K
+16.66%
Ms. Kerrii B. Anderson, CPA
Ms. Kerrii B. Anderson, CPA
Independent Director
Independent Director
5.17K
-59.21%
Mr. Mark S. Schroeder
Mr. Mark S. Schroeder
Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer
Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer
4.96K
--
Mr. Akinbolade Oyegunwa
Mr. Akinbolade Oyegunwa
Executive Vice President and Chief Information and Technology Officer
Executive Vice President and Chief Information and Technology Officer
3.46K
+16.48%
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Adam H. Schechter
Mr. Adam H. Schechter
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
98.96K
-5.81%
Dr. Brian J. Caveney, M.D., J.D.
Dr. Brian J. Caveney, M.D., J.D.
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
30.07K
-6.24%
Mr. Lance V. Berberian
Mr. Lance V. Berberian
Executive Vice President - Special Advisor, Strategy
Executive Vice President - Special Advisor, Strategy
22.53K
+9.59%
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Independent Director
Independent Director
12.89K
--
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Lead Independent Director
Lead Independent Director
12.84K
--
Ms. Richelle P. Parham
Ms. Richelle P. Parham
Independent Director
Independent Director
9.48K
--
收入明细
单位: USD更新时间: 3月12日 周三
单位: USD更新时间: 3月12日 周三
FY2021
FY2020
FY2019
暂无数据
地区USD
名称
营收
占比
Northern America
13.09B
81.22%
Europe
2.05B
12.72%
Other Countries
976.40M
6.06%
业务
地区
暂无数据
股东统计
更新时间: 5月16日 周五
更新时间: 5月16日 周五
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
11.68%
BlackRock Institutional Trust Company, N.A.
5.56%
State Street Global Advisors (US)
4.62%
Select Equity Group, L.P.
2.68%
Geode Capital Management, L.L.C.
2.50%
Other
72.97%
持股股东
持股股东
占比
The Vanguard Group, Inc.
11.68%
BlackRock Institutional Trust Company, N.A.
5.56%
State Street Global Advisors (US)
4.62%
Select Equity Group, L.P.
2.68%
Geode Capital Management, L.L.C.
2.50%
Other
72.97%
股东类型
持股股东
占比
Investment Advisor
53.64%
Investment Advisor/Hedge Fund
34.33%
Research Firm
3.26%
Pension Fund
2.10%
Hedge Fund
1.84%
Bank and Trust
1.45%
Sovereign Wealth Fund
1.31%
Individual Investor
0.39%
Insurance Company
0.06%
Other
1.63%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
1819
81.60M
98.43%
-5.15M
2025Q1
1872
81.69M
97.58%
-5.17M
2024Q4
1872
81.10M
96.90%
-5.32M
2024Q3
1856
80.09M
95.55%
-6.82M
2024Q2
1876
81.29M
96.43%
-7.49M
2024Q1
1904
82.39M
97.73%
-8.65M
2023Q4
1947
83.11M
99.02%
-9.76M
2023Q3
1930
84.34M
99.29%
-7.18M
2023Q2
1934
84.05M
94.75%
-3.56M
2023Q1
1940
82.33M
92.89%
-5.93M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
9.69M
11.57%
+71.11K
+0.74%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.61M
5.5%
+61.07K
+1.34%
Mar 31, 2025
State Street Global Advisors (US)
3.83M
4.57%
+123.43K
+3.33%
Mar 31, 2025
Select Equity Group, L.P.
2.22M
2.65%
+624.10K
+39.11%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.07M
2.47%
+64.83K
+3.24%
Mar 31, 2025
Allspring Global Investments, LLC
1.96M
2.34%
+40.81K
+2.13%
Mar 31, 2025
Diamond Hill Capital Management Inc.
1.95M
2.33%
-15.51K
-0.79%
Mar 31, 2025
BlackRock Financial Management, Inc.
1.85M
2.21%
-72.89K
-3.79%
Mar 31, 2025
Nordea Funds Oy
1.43M
1.71%
+374.30K
+35.55%
Mar 31, 2025
Fidelity Management & Research Company LLC
1.30M
1.56%
+88.25K
+7.26%
Mar 31, 2025
查看更多
持股ETF
更新时间: 6 小时前
更新时间: 6 小时前
机构名称
占比
iShares U.S. Healthcare Providers ETF
3.47%
Knowledge Leaders Developed World ETF
3.01%
Thrivent Small-Mid Cap ESG ETF
2.24%
iShares Health Innovation Active ETF
2.01%
Strategas Global Policy Opportunities ETF
1.97%
SPDR S&P Health Care Services ETF
1.93%
iShares Large Cap Value Active ETF
1.92%
Invesco S&P 500 Equal Weight Health Care ETF
1.67%
Brandes US Value ETF
1.62%
Franklin Genomic Advancements ETF
1.54%
查看更多
iShares U.S. Healthcare Providers ETF
占比3.47%
Knowledge Leaders Developed World ETF
占比3.01%
Thrivent Small-Mid Cap ESG ETF
占比2.24%
iShares Health Innovation Active ETF
占比2.01%
Strategas Global Policy Opportunities ETF
占比1.97%
SPDR S&P Health Care Services ETF
占比1.93%
iShares Large Cap Value Active ETF
占比1.92%
Invesco S&P 500 Equal Weight Health Care ETF
占比1.67%
Brandes US Value ETF
占比1.62%
Franklin Genomic Advancements ETF
占比1.54%
分红派息
近5年累计派现 692.30M 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Jan 09, 2025
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Mar 12, 2025 going ex on Feb 27, 2025
Feb 27, 2025
Mar 12, 2025
Feb 27, 2025
Oct 10, 2024
LH.NB Final Cash Dividend of gross USD 0.72 paid on Dec 13, 2024 going ex on Nov 26, 2024
Nov 26, 2024
Dec 13, 2024
Nov 26, 2024
Jul 25, 2024
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Sep 13, 2024 going ex on Aug 29, 2024
Aug 29, 2024
Sep 13, 2024
Aug 29, 2024
Apr 11, 2024
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Jun 12, 2024 going ex on May 24, 2024
May 28, 2024
Jun 12, 2024
May 24, 2024
Jan 12, 2024
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Mar 13, 2024 going ex on Feb 26, 2024
Feb 27, 2024
Mar 13, 2024
Feb 26, 2024
Oct 12, 2023
LH.NB Final Cash Dividend of gross USD 0.72 paid on Dec 12, 2023 going ex on Nov 07, 2023
Nov 08, 2023
Dec 12, 2023
Nov 07, 2023
Jul 13, 2023
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Sep 08, 2023 going ex on Aug 07, 2023
Aug 08, 2023
Sep 08, 2023
Aug 07, 2023
Apr 06, 2023
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Jun 08, 2023 going ex on May 17, 2023
May 18, 2023
Jun 08, 2023
May 17, 2023
Jan 12, 2023
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Mar 13, 2023 going ex on Feb 22, 2023
Feb 23, 2023
Mar 13, 2023
Feb 22, 2023
Oct 12, 2022
LH.NB Final Cash Dividend of gross USD 0.72 paid on Dec 09, 2022 going ex on Nov 16, 2022
Nov 17, 2022
Dec 09, 2022
Nov 16, 2022
查看更多
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
tradingkey.logo
tradingkey.logo
日内数据由路孚特(Refinitiv)提供,并受使用条款约束。历史及当前收盘数据均由路孚特提供。所有报价均以当地交易所时间为准。美股报价的实时最后成交数据仅反映通过纳斯达克报告的交易。日内数据延迟至少15分钟或遵循交易所要求。
* 参考、分析和交易策略由第三方提供商Trading Central提供,观点基于分析师的独立评估和判断,未考虑投资者的投资目标和财务状况。
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有
KeyAI